PhioPharma

[PhioPharma @phio_pharma]

Phio will be presenting new preclinical data on the combination of an INTASYL compound targeting CTLA-4 and a systemic anti-PD-1 antibody demonstrating enhanced tumor control at #SITC23 from Nov 1-5 in San Diego. More details can be found here: https://t.co/JCEwmcMExV

[PhioPharma @phio_pharma]

Phio will be presenting data on preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Oct 11 -15. Learn about our presentations here: https://t.co/7KsxPqGBkp
#Targets23

[PhioPharma @phio_pharma]

Phio’s CEO will be presenting at the HCW Annual Global Investment Conference being held in New York from Sept. 11 – 13th where he will discuss the recent FDA IND approvals for Phio’s lead product, PH-762. Read here for more details: https://t.co/GoaB89rnbX

[PhioPharma @phio_pharma]

Phio Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx and Providence Cancer Institute. The clinical trial is one of two studies cleared by the FDA which will utilize Phio’s lead product candidate, PH-762. Read more here: https://t.co/bZYsqxvDxU

[PhioPharma @phio_pharma]

Phio announces FDA clearance to initiate clinical trial of PH-762, its lead RNAi product candidate, for the treatment of skin cancers. Refer below for more details: https://t.co/EZ6hzFdzFO

[PhioPharma @phio_pharma]

Phio will be presenting a new poster titled “Self-Delivering RNAi (INTASYL™) Compounds Targeting TIGIT or CBL-B Improve NK Cell Functional Cytotoxicity toward Tumor Cells” at #ASGCT23 in LA on May 17th at 12pm PT.

[PhioPharma @phio_pharma]

Looking forward to attending #AACR23 where we will be presenting two posters about INTASYL. INTASYL is our proprietary self-delivering RNAi technology that is designed to make immune cells more effective in killing tumor cells. Check out our website for details.

[PhioPharma @phio_pharma]

Phio Reports FY 2022 #Financial Results and Provides Business Update. Refer to the below link for further details: https://t.co/apnRSyJDge

[PhioPharma @phio_pharma]

Robert (Bob) Bitterman, who’s been serving as Interim CEO of Phio, has accepted the position of President and CEO. He’ll also continue to serve as Chair of the Board. Welcome to the team Bob! Read more here: https://t.co/FRXqLqCRt4
#RNAi #immunooncology #dermatology

[PhioPharma @phio_pharma]

Positive recommendation from an independent data monitoring committee’s review of interim safety data from our Phase 1b clinical trial of PH-762 for the treatment of advanced #Melanoma to proceed with enrollment of the next dose cohort. Read more here: https://t.co/6eAqlT46KS

[PhioPharma @phio_pharma]

Phio announces it has received regulatory clearance of its #clinicaltrial with PH-762 and our partner AgonOx’s tumor infiltrating lymphocytes to treat solid tumors. Details here: https://t.co/3imFNrjU1A

[PhioPharma @phio_pharma]

Phio expects to file an IND in the US for a Phase 1b #clinicaltrial of PH-762 for the treatment of cutaneous squamous cell carcinoma in the first half of 2023. Read more here: https://t.co/OPE0V2gmMN

[PhioPharma @phio_pharma]

Phio presented new data at #SITC2022 showing our INTASYL™ compounds demonstrated activity against multiple protein targets involved in #cancer, including PD-1, BRD4, CTLA-4, TIGIT and CTGF. See more details here: https://t.co/MeMQ0ScDlw

[PhioPharma @phio_pharma]

Phio will provide an update on its first clinical trial with PH-762; demonstrate the potential of PH-762 to further enhance TILs; and new preclinical data on relevant targets in immunotherapy at #SITC22. Learn more about our six presentations here: https://t.co/nfFcbapHup

[PhioPharma @phio_pharma]

Phio is pleased to announce the appointment of Robert Bitterman as Executive Chairman. Read here for more details: https://t.co/PoeEiJXplH

[PhioPharma @phio_pharma]

Our partners at Helmholtz presented preclinical data at ITOC9 showing PH-762 enhances the persistence of the T cell population expressing stem cell-like characteristics, which is expected to result in enhanced duration of anti-tumor activity. Read here: https://t.co/Z2uLfCjffT

[PhioPharma @phio_pharma]

New data on neoadjuvant treatments presented at #ASCO20202 further supports the concept of our neoadjuvant clinical trial in patients with advanced melanoma.

[PhioPharma @phio_pharma]

Phio presents a trial-in-progress poster at #ASCO2022 on the study outline of its Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma. Check out our poster here: https://t.co/ucFL8cLWOo

[PhioPharma @phio_pharma]

May is National Cancer Research Month. In its honor, Phio would like to thank all the scientists who are working tirelessly to find new cancer treatment options, including our own R&D team members. #CancerResearch #NationalCancerResearchMonth

[PhioPharma @phio_pharma]

Phio Presents New Data at #ASGCT22 Demonstrating that PH-894 Enhances the Activity of HER2-CAR-T Cells. For further details: https://t.co/gr9IF9M5Eo